|1.||Moore, Bob M: 2 articles (11/2012 - 04/2006)|
|2.||Duntsch, Christopher: 2 articles (11/2012 - 04/2006)|
|3.||Abidi, Ammaar H: 1 article (11/2012)|
|4.||Keir, Stephen T: 1 article (11/2012)|
|5.||Bigner, Darell D: 1 article (11/2012)|
|6.||Guan, Peihong: 1 article (11/2012)|
|7.||Kosanke, Stanley D: 1 article (11/2012)|
|8.||Gurley, Steven N: 1 article (11/2012)|
|9.||Allison, Patrick: 1 article (11/2012)|
|10.||Elberger, Andrea J: 1 article (11/2012)|
04/01/2006 - "Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma."
04/01/2006 - "These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma."
04/01/2006 - "To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma. "
11/01/2012 - "Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233."
04/01/2006 - "The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety. "
11/01/2012 - "The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. "
04/01/2006 - "A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration. "
04/01/2006 - "Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration. "
|1.||Heterologous Transplantation (Xenotransplantation)